LeadingBiotech: Cancer Advance is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Scott DeWire, Ph.D.
Global Head of Business Development for Cancer Immunology at Boehringer Ingelheim


Scott is responsible for business development and licensing at Boehringer Ingelheim’s Cancer Immunology and Biotherapeutics groups.  BI has several academic and biotech partners in the fields of oncolytic virotherapy and viral vector vaccines.  Most notably, in September of 2018 after a two-year collaborative partnership, BI acquired Vira Therapeutics of Innsbruck, Austria.

Scott holds a PhD from the University of North Carolina, where he studied herpesvirus replication and latency. He completed his postdoc in the lab of Nobel Laureate Robert Lefkowitz, MD at Duke University.  Scott next co-founded Trevena Inc, a GPCR-focused biotech headquartered in Philadelphia, where he was the Assistant Director of Biology.  Since joining BI in 2012, Scott held various roles in the research group before joining BD&L in 2016. 

Agenda Sessions

  • Therapeutic Focus: Oncolytic Viruses


Speakers at this event